Every 10-Q that DROR ORTHO-DESIGN INC (DROR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DROR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DROR filings page.
Dror Ortho-Design, Inc., a development-stage orthodontic device company, reports continued losses for the quarter ended June 30, 2026 while advancing its AI-based aligner platform toward FDA 510(k) submission. The company has not generated material revenues and remains focused on research and development and corporate overhead.
For the quarter, net loss was $625,143, and for the first half of 2026 net loss was $1,263,809, driven by research and development expenses of $269,179 and general and administrative expenses of $723,781 over six months. Operating cash outflow was $709,019 in the half year, partially offset by $575,000 of new convertible debentures.
As of June 30, 2026 total assets were $365,689 against liabilities of $4,303,209, including $1,873,777 of convertible promissory notes, a $993,779 derivative warrant liability and a $520,000 registration rights liability, resulting in a stockholders’ deficit of $3,937,520 and negative working capital of $3,751,932. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing while targeting about $1.5 million of spending over 18 months to advance its platform and regulatory efforts.
Dror Ortho-Design, Inc. reported a first-quarter 2026 net loss of $638,666 as it continues developing its orthodontic alignment platform with no material revenues. Operating expenses were $497,194, mainly research and development and general and administrative costs.
Cash fell to $23,802 at March 31, 2026, while total liabilities reached $3,566,158 against total assets of $253,781, resulting in a stockholders’ deficit of $3,312,377. Management disclosed substantial doubt about the company’s ability to continue as a going concern and is relying on bridge debentures from existing investors and future capital raises to fund operations.
The company is advancing an AI-based orthodontic platform and expects to spend about $1.5 million over 18 months on development and regulatory work. It also noted regional war risks in Israel, though impacts to date were described as immaterial. In April 2026, it added new bridge financing and appointed Ran Israeli as Chief Financial Officer.
Dror Ortho-Design, Inc., a pre-revenue Israeli orthodontic device developer, reported a net loss of $653,528 for the quarter and $1,988,989 for the nine months ended September 30, 2025, narrower than a year ago as research and development and share-based compensation declined.
Cash fell to $240,362 with total assets of $271,218, while current liabilities reached $2,420,477, resulting in a stockholders’ deficit of $2,317,813. Management states there is substantial doubt about the company’s ability to continue as a going concern and it remains dependent on external financing.
During the first nine months of 2025 Dror raised $1,100,000 via zero-interest convertible debentures that may convert into common shares in a future public offering and created a derivative warrant liability of $478,285. The company continues developing its AI-based, sleep-time orthodontic alignment platform and plans to seek new FDA 510(k) clearance for this updated device.